Skip to main content
. 2021 Sep 7;28(7-8):801–809. doi: 10.3727/096504021X16218531628569

Table 2.

Adverse Events of 70 mCRC Patients

Adverse Events Grade 0 Grade 1 Grade 2 Grade 3 Grade 4
Study
[n (%)]
Control
[n (%)]
Study
[n (%)]
Control
[n (%)]
Study
[n (%)]
Control
[n (%)]
Study
[n (%)]
Control
[n (%)]
Study
[n (%)]
Control
[n (%)]
Gastrointestinal toxicities
 Diarrhea 193 (94.6) 170 (85.4) 7 (3.4) 17 (8.5) 4 (2.0) 8 (4.0) 0 4 (2.0) 0 0
 Nausea 149 (73.0) 119 (66.5) 48 (23.5) 62 (31.2) 7 (3.4) 16 (8.0) 0 2 (1.0) 0 0
 Vomiting 181 (88.7) 168 (48.1) 15 (7.4) 15 (7.5) 8 (3.9) 13 (6.5) 0 3 (1.5) 0 0
Hepatic toxicities
 Increased SGOT level 168 (82.4) 173 (86.9) 31 (15.2) 21 (10.6) 5 (2.5) 3 (1.5) 0 1 (0.5) 0 1 (0.5)
 Increased SGPT level 175 (85.8) 173 (86.9) 27 (13.2) 24 (12.1) 2 (1.0) 0 0 1 (0.5) 0 1 (0.5)
Hematologic toxicities
 Leukopenia 152 (74.5) 126 (63.3) 41 (20.1) 47 (23.6) 11 (5.4) 25 (12.6) 0 1 (0.5) 0 0
 Anemia 44 (21.6) 68 (34.2) 115 (56.4) 98 (49.2) 45 (22.1) 33 (16.6) 0 0 0 0

Abbreviations: SGOT, serum glutamic oxaloacetic transaminase; SGPT, serum glutamic pyruvic transaminase.